Shares of Amedisys Inc. (NASDAQ:AMED) have received a consensus recommendation of “Hold” from the ten ratings firms that are presently covering the company. Seven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $51.80.
Several equities research analysts have issued reports on the stock. Wells Fargo & Co. reiterated a “buy” rating on shares of Amedisys in a research report on Sunday, September 11th. Jefferies Group restated a “buy” rating on shares of Amedisys in a report on Tuesday, September 6th. Zacks Investment Research upgraded shares of Amedisys from a “sell” rating to a “hold” rating in a report on Thursday, August 4th. Mizuho lowered shares of Amedisys from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $57.00 to $55.00 in a report on Wednesday, August 3rd. Finally, Stephens initiated coverage on shares of Amedisys in a report on Thursday, June 16th. They issued an “equal weight” rating and a $55.00 price objective for the company.
Shares of Amedisys (NASDAQ:AMED) opened at 47.44 on Monday. Amedisys has a 12 month low of $31.16 and a 12 month high of $55.16. The company has a market capitalization of $1.59 billion, a PE ratio of 41.50 and a beta of 1.05. The firm’s 50-day moving average is $48.27 and its 200 day moving average is $49.66.
Amedisys (NASDAQ:AMED) last announced its earnings results on Tuesday, August 2nd. The company reported $0.42 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.42. Amedisys had a net margin of 2.78% and a return on equity of 12.17%. The business earned $360 million during the quarter, compared to analyst estimates of $353.07 million. During the same period in the previous year, the business posted $0.43 earnings per share. Amedisys’s revenue for the quarter was up 14.8% on a year-over-year basis. Equities research analysts predict that Amedisys will post $1.69 EPS for the current year.
A number of large investors have recently bought and sold shares of the stock. Acrospire Investment Management LLC purchased a new stake in Amedisys during the first quarter worth approximately $108,000. Invictus RG increased its position in shares of Amedisys by 152.7% in the second quarter. Invictus RG now owns 2,813 shares of the company’s stock worth $142,000 after buying an additional 1,700 shares during the last quarter. PineBridge Investments L.P. increased its position in shares of Amedisys by 2.9% in the second quarter. PineBridge Investments L.P. now owns 3,560 shares of the company’s stock worth $180,000 after buying an additional 101 shares during the last quarter. Teacher Retirement System of Texas increased its position in shares of Amedisys by 21.6% in the second quarter. Teacher Retirement System of Texas now owns 3,780 shares of the company’s stock worth $191,000 after buying an additional 672 shares during the last quarter. Finally, ProShare Advisors LLC bought a new position in shares of Amedisys during the second quarter worth about $204,000. Institutional investors own 91.45% of the company’s stock.
Amedisys Company Profile
Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.
Receive News & Ratings for Amedisys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.